Protocol Title: Phase 2 Study Comparing Efficacy and Safety of ABT-165 + FOLFIRI vs Bevacizumab + FOLFIRI in Metastatic Colorectal Cancer Previously Treated with Fluoropyrimidine/Oxaliplatin and Bevacizumab

Target Population: Metastatic Colorectal Cancer

Summary: A study to evaluate the efficacy and tolerability of ABT-165 + FOLFIRI compared to Bevacizumab + FOLFIRI in participants with previously treated Metastatic Adenocarcinoma of the Colon or Rectum.

Key Inclusion Criteria:
- Diagnosis of histologically or cytologically confirmed Metastatic Adenocarcinoma of the Colon or Rectum.
- ≥ 1 unresectable lesion on a CT scan that is measurable as defined by RECIST.
- ECOG Performance Status Score of 0-1.
- Progression following treatment with Fluoropyrimidine / Oxaliplatin / Bevacizumab-regimen in the metastatic setting.
- Adequate hematologic, renal and hepatic function.

Key Exclusion Criteria:
- Any prior therapy with Irinotecan.
- Unresolved clinically significant toxicities from prior anticancer therapy, defined as any CTCAE ≥ Grade 2.
- Clinically significant conditions that increase the risk for antiangiogenic therapy.
- History of any of the following during first-line therapy with a Bevacizumab-containing regimen:
  - Arterial thrombotic / thromboembolic event
  - Bowel perforation
  - Grade 4 hypertension
  - Grade 3 proteinuria
  - Grade 3-4 bleeding events

Contacts:
- Principal Investigator: Marc Matrana, MD
- Research Nurses (RN): Sharon Jerdonek (sharon.jerdonek@ochsner.org, ext. 23929)
  Amanda Woolery (amanda.woolery@ochsner.org, ext. 20275)

For additional information: https://clinicaltrials.gov/ct2/show/NCT03368859